+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epigenetic Therapeutics: Global Markets

  • PDF Icon

    Report

  • 155 Pages
  • June 2023
  • Region: Global
  • BCC Research
  • ID: 5819618
Description Jump to:

This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

This report, however, does not cover epigenetic diagnostic assays and instruments.

Report Includes

  • 77 tables
  • A comprehensive overview of the global markets for epigenetic therapeutics
  • Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
  • In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
  • Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
  • A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
  • Review of patent trends and research publications for innovations in the genome-editing technologies
  • Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
  • Analysis of the competitive environment and market opportunities based on the company’s business strategies, product mapping, and operational integration
  • Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Research Reports
Chapter 2 Summary and Highlights
  • Highlights of the Market for Epigenetic Therapeutics
Chapter 3 Market Overview and Definitions
  • Overview
  • Epigenetics
Chapter 4 Market Trends
  • Market Drivers
  • Aging Population
  • Risk of Cancer in Major Countries
  • Penetration of Targeted Medicine in Emerging Markets
  • Market Opportunity
  • Market Restraints
Chapter 5 Market Breakdown by Product Type
  • Introduction
  • Prap Inhibitors
  • Kinase Inhibitors
  • Idh Inhibitors
  • Hdac Inhibitors
  • Dnmt Inhibitors
  • Kmt Inhibitors
Chapter 6 Impact of Covid-19
  • Introduction
  • Impact of Covid-19 on the Medical Devices and Pharmaceutical Industries
  • Decline/Delay in Elective Procedures
  • Impact of Covid-19 on Medical Device and Pharmaceutical Product Segments
  • Impact of Covid-19 on Epigenetic Therapeutics Markets
Chapter 7 Market Breakdown by Region
  • Market Overview and Discussion
  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 8 Emerging/Upcoming Technologies
  • Crispr
  • Antibody Drug Conjugates
  • Multitargeting Agents
Chapter 9 Competitive Landscape
  • Industry Scenario
  • Company Shares
Chapter 10 Patent Analysis
  • Patent Analysis, by Manufacturer
Chapter 11 Pipeline Analysis
  • Clinical Trials Scenario
Chapter 12 Company Profiles
  • Astrazeneca
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Gsk plc
  • Incyte
  • Ipsen
  • Seagen
  • Servier Laboratories, Ltd.
Chapter 13 Appendix: Acronyms
List of Tables
Summary Table: Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 1: Global Population, Age 60 and Older, 2010-2050
Table 2: Incidence of Pancreas Cancer, 2020-2040
Table 3: Incidence of Trachea, Bronchus and Lung Cancer, 2020-2040
Table 4: Incidence of Melanoma Cancer, 2020-2040
Table 5: Incidence of Prostate Cancer, 2020-2040
Table 6: Incidence of Breast Cancer, 2020-2040
Table 7: Incidence of Kidney and Renal Pelvis Cancers, 2020-2040
Table 8: Incidence of Hodgkin Lymphoma Cancer, 2020-2040
Table 9: Incidence of Non-Hodgkin Lymphoma Cancer, 2020-2040
Table 10: Incidence of Multiple Myeloma and Immunoproliferative Diseases, 2020-2040
Table 11: Incidence of Leukemia Cancer, 2020-2040
Table 12: Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 13: Global PRAP Inhibitors Market, by Region, Through 2028
Table 14: Global Kinase Inhibitors Market, by Region, Through 2028
Table 15: Global IDH Inhibitors Market, by Region, Through 2028
Table 16: Global HDAC Inhibitors Market, by Region, Through 2028
Table 17: Global DNMT Inhibitors Market, by Region, Through 2028
Table 18: Global KMT Inhibitors Market, by Region, Through 2028
Table 19: Global Epigenetic Therapeutics Market, by Region, Through 2028
Table 20: North American Epigenetic Therapeutics Market, by Country, Through 2028
Table 21: Latin American Epigenetic Therapeutics Market, by Country, Through 2028
Table 22: European Epigenetic Therapeutics Market, by Country, Through 2028
Table 23: Asia-Pacific Epigenetic Therapeutics Market, by Country, Through 2028
Table 24: RoW Epigenetic Therapeutics Market, Through 2028
Table 25: Patents on Epigenetic Drugs, 2015-April 2023
Table 26: Selected Manufacturer Patents on Epigenetic Drugs, 2015-April 2023
Table 27: Patents on HDAC Inhibitors, 2015-April 2023
Table 28: Selected Manufacturer Patents on HDAC inhibitors, 2015-April 2023
Table 29: Patents on Kinase inhibitors, 2015-April 2023
Table 30: Patents on Verinostat Drug, 2015-April 2023
Table 31: Selected Manufacturer Patents on Verinostat Drug, 2015-April 2023
Table 32: Patents on Romidepsin Drug, 2015-April 2023
Table 33: Selected Manufacturer Patents on Romidepsin Drug, 2015-April 2023
Table 34: Patents on Panobinostat Drug, 2015-April 2023
Table 35: Selected Manufacturer Patents on Panobinostat Drug, 2015-April 2023
Table 36: Patents on Belinostat, 2015-April 2023
Table 37: Selected Manufacturer Patents on Belinostat, 2015-April 2023
Table 38: Patents on Tucidinostat Drug, 2015-April 2023
Table 39: Selected Manufacturer Patents on Tucidinostat Drug, 2015-April 2023
Table 40: Patents on 5-Azacytidine Drug, 2015-April 2023
Table 41: Selected Manufacturer Patents on 5-Azacytidine Drug, 2015-April 2023
Table 42: Patents on 5-Aza-2’-Deoxycytidine Drug, 2015-April 2023
Table 43: Selected Manufacturer Patents on 5-Aza-2’-Deoxycytidine Drug, 2015-April 2023
Table 44: Patents on Pinometostat Drug, 2015-April 2023
Table 45: Selected Manufacturer Patents on Pinometostat Drug, 2015-April 2023
Table 46: Patents on Ruxolitinib Drug, 2015-April 2023
Table 47: Selected Manufacturer Patents on Ruxolitinib Drug, 2015-April 2023
Table 48: Patents on AZD1152 Drug, 2015-April 2023
Table 49: Selected Manufacturer Patents on AZD1152 Drug, 2015-April 2023
Table 50: Patents on Olaparib Drug, 2015-April 2023
Table 51: Selected Manufacturer Patents on Olaparib Drug, 2015-April 2023
Table 52: Patents on Veliparib Drug, 2015-April 2023
Table 53: Selected Manufacturer Patents on Veliparib Drug, 2015-April 2023
Table 54: Patents on Niraparib Drug, 2015-April 2023
Table 55: Selected Manufacturer Patents on Niraparib Drug, 2015-April 2023
Table 56: Patents on Rucaparib Drug, 2015-April 2023
Table 57: Selected Manufacturer Patents on Rucaparib Drug, 2015-April 2023
Table 58: Patents on Talazoparib Drug, 2015-April 2023
Table 59: Selected Manufacturer Patents on Talazoparib Drug, 2015-April 2023
Table 60: Selected Kinase Inhibitors in Clinical Trials, as of 2023
Table 61: Selected Olaparib Inhibitors in Clinical Trials, as of 2023
Table 62: Selected Romidepsin Inhibitors in Clinical Trials, as of 2023
Table 63: Selected Ruxolitinib Inhibitors in Clinical Trials, as of 2023
Table 64: AstraZeneca: Company Annual Revenue, 2019-2022
Table 65: AstraZeneca: Annual Revenue, by Product, 2022
Table 66: Bristol-Myers Squibb: Company Annual Revenue, 2019-2022
Table 67: Clovis Oncology: Revenue, 2019-2021
Table 68: GSK: Company Annual Revenue, 2019-2022
Table 69: GSK: Annual Revenue, by Product, 2022
Table 70: Incyte: Company Annual Revenue, 2019-2021
Table 71: Incyte: Product Revenue, 2019-2021
Table 72: Ipsen: Sales Revenue, 2021 and 2022
Table 73: Ipsen: Sales Revenue, by Segment, 2021 and 2022
Table 74: Ipsen: Sales Revenue, by Region, 2021 and 2022
Table 75: Seagen: Company Annual Revenue, 2019-2021
Table 76: Acronyms Used in this Report

List of Figures
Summary Figure A: Global Epigenetic Therapeutics Market, by Product Type, 2019-2028
Summary Figure B: Global Epigenetic Therapeutics Market Share, by Product Type, 2022
Figure 1: Global Epigenetic Therapeutics Market, by Product, 2020-2028
Figure 2: Global Epigenetic Therapeutics Market Share, by Product, 2022
Figure 3: Global PRAP Inhibitors Market, by Region, 2020-2028
Figure 4: Global PRAP Inhibitors Market Share, by Region, 2022
Figure 5: Global Kinase Inhibitors Market, by Region, 2020-2028
Figure 6: Global Kinase Inhibitors Market Share, by Region, 2022
Figure 7: Global IDH Inhibitors Market, by Region, 2020-2028
Figure 8: Global IDH Inhibitors Market Share, by Region, 2022
Figure 9: Global HDAC Inhibitors Market, by Region, 2020-2028
Figure 10: Global HDAC Inhibitors Market Share, by Region, 2022
Figure 11: Global DNMT Inhibitors Market, by Region, 2020-2028
Figure 12: Global DNMT Inhibitors Market Share, by Region, 2022
Figure 13: Global KMT Inhibitors Market, by Region, 2020-2028
Figure 14: Global KMT Inhibitors Market Share, by Region, 2022
Figure 15: Global Epigenetic Therapeutics Market Share, by Region, 2022
Figure 16: North American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 17: Latin American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 18: European Epigenetic Therapeutics Market Share, by Country, 2022
Figure 19: Asia-Pacific Epigenetic Therapeutics Market Share, by Country, 2022
Figure 20: Global Epigenetic Therapeutics Market Share, by Company, 2022
Figure 21: Global PRAP Inhibitors Market Share, by Company, 2022
Figure 22: Global Kinase Inhibitors Market Share, by Company, 2022
Figure 23: Global IDH Inhibitors Market Share, by Company, 2022
Figure 24: Global HDAC Inhibitors Market Share, by Company, 2022
Figure 25: Global DNMT Inhibitors Market Share, by Company, 2022
Figure 26: Global KMT Inhibitors Market Share, by Company, 2022
Figure 27: AstraZeneca: Sales Share, by Product, 2022
Figure 28: AstraZeneca: Sales Share, by Region, 2022
Figure 29: Bristol-Myers Squibb: Sales Share, by Region, 2022
Figure 30: GSK: Revenue Share, by Product, 2022
Figure 31: GSK: Sales Share, by Region, 2022
Figure 32: Ipsen: Sales Revenue Share, by Segment, 2022
Figure 33: Ipsen: Sales Revenue Share, by Region 2022

Executive Summary

The global epigenetic therapeutics market was valued at $6.4 billion in 2022. The market is expected to reach $9.8 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.7% over the forecast period. Growth factors include aging populations, increased frequency of cancer risk associated with aging and increased prevalence of cancers cases such as acute-T-cell leukemia, breast cancer, ovarian cancer, Non-Small-Cell lung cancers. Epigenetic drug therapy serves as an ultimate treatment option when a cancer patient is not responding to the conventional therapies such as chemotherapy.

Technological innovations in epigenetic drug discovery and development are driving increased use of epigenetic therapeutics, which also is pushing market growth. However, loss of exclusivity in the case of a few branded drugs and the entry of generic drugs into the market is the restraining the growth of this market.

In 2022, the PRAP inhibitors segment held the largest share of the global market for epigenetic therapeutics, with 51.7% of the market, followed by Kinase inhibitors (37.5%), HDAC inhibitors (5.8%), IDH inhibitors (2.8%), DNMT inhibitors (1.9%) and KMT inhibitors (0.2%)

Companies Mentioned

  • Astrazeneca
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Gsk plc
  • Incyte
  • Ipsen
  • Seagen
  • Servier Laboratories, Ltd.

Table Information

Report AttributeDetails
No. of Pages155
PublishedJune 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 6.8 Billion
Forecasted Market Value ( USD ) by 2028 $ 9.8 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Epigenetics Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Epigenetics Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 190 Pages
  • Global
From
Epigenetic Regulation of Cancer - Part A. International Review of Cell and Molecular Biology Volume 380 - Product Image

Epigenetic Regulation of Cancer - Part A. International Review of Cell and Molecular Biology Volume 380

  • Book
  • Global
Epigenetics Global Market Report 2024 - Product Image

Epigenetics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Epigenetics Market by Product, Technique, Methods, Application, End User - Global Forecast 2025-2030 - Product Image

Epigenetics Market by Product, Technique, Methods, Application, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology), and Region - Forecast to 2028 - Product Image

Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology), and Region - Forecast to 2028

  • Report
  • 353 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.